Core Viewpoint - IMUNON, Inc. is set to announce topline results from the Phase 2 OVATION 2 Study of its DNA-mediated immunotherapy, IMNN-001, for advanced ovarian cancer on July 30, 2024, at 8:00 a.m. Eastern time, followed by a conference call at 8:30 a.m. Eastern time to discuss the results [1]. Group 1: Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [4]. - The company is advancing its non-viral DNA technology, with its first modality, TheraPlas®, designed for coding cytokines and therapeutic proteins for solid tumors, and a second modality, PlaCCine®, for delivering DNA-coded viral antigens [4]. Group 2: Clinical Programs - The lead clinical program, IMNN-001, is a DNA-based immunotherapy currently in Phase 2 development for localized treatment of advanced ovarian cancer, which instructs the body to produce cancer-fighting molecules at the tumor site [5]. - IMUNON has also initiated a first-in-human study for its COVID-19 booster vaccine, IMNN-101, and aims to leverage its technological advancements to better serve patients with challenging conditions [5].
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow